


Supplementary Materials: Urinary Polycyclic Aromatic Hydrocarbon Metabolites Are Associated with Biomarkers of Chronic Endocrine Stress, Oxidative Stress, and Inflammation in Adolescents: FLEHS-4 (2016–2020)

Veerle J Verheyen, Sylvie Remy, Eva Govarts, Ann Colles, Laura Rodriguez Martin, Gudrun Koppen, Stefan Voorspoels, Liesbeth Bruckers, Esmée M Bijnens, Stijn Vos, Bert Morrens, Dries Coertjens, Annelies De Decker, Carmen Franken, Elly Den Hond, Vera Nelen, Adrian Covaci, Ilse Loots, Stefaan De Henauw, Nicolas Van Larebeke, Caroline Teughels, Tim S Nawrot and Greet Schoeters



[Leaflet](#) | Map data © [OpenStreetMap](#) contributors, [CC-BY-SA](#), | Source : [Statbel](#) | Réalisation : [UMONS](#) Université de Mons

Figure S1. Area Deprivation Index in Flanders at municipal level (2017), according to Lahaye, W., Pannecoucke, I., & Sansen, F. (2019). Kinderarmoede en het lokale niveau—De gemeenten in kaart | Koning Boudewijnstichting. https://www.kbs-frb.be/nl/kinderarmoede_inkaart.

Table S1. Pearson's correlations between PAH exposure biomarkers and effect biomarkers in Flemish adolescents ($n = 393$, except noted differently).

| | | 1-OHPy | 2-OHNa | 2,3-OHFl | 2-OHPH | 3-OHPH | 1,9-OHPH | Σ OH-PAHs | HCC | Leukocytes | Neutrophils | Lymphocytes | Monocytes | NLR | 8-oxodG |
|-----------------------------------|---------------|-------------|-------------|-------------|-------------|-------------|-------------|------------------|-------------|-------------|-------------|--------------|-------------|------|---------|
| 1-OHPy | Pearson's r | 1 | | | | | | | | | | | | | |
| | n | 391 | | | | | | | | | | | | | |
| 2-OHNa | Pearson's r | 0.23 | 1 | | | | | | | | | | | | |
| | n | 391 | 392 | | | | | | | | | | | | |
| 2,3-OHFl | Pearson's r | 0.62 | 0.27 | 1 | | | | | | | | | | | |
| | n | 391 | 392 | 392 | | | | | | | | | | | |
| 2-OHPH | Pearson's r | 0.61 | 0.19 | 0.64 | 1 | | | | | | | | | | |
| | n | 391 | 392 | 392 | 393 | | | | | | | | | | |
| 3-OHPH | Pearson's r | 0.70 | 0.18 | 0.69 | 0.81 | 1 | | | | | | | | | |
| | n | 391 | 392 | 392 | 393 | 393 | | | | | | | | | |
| 1,9-OHPH | Pearson's r | 0.61 | 0.18 | 0.54 | 0.52 | 0.71 | 1 | | | | | | | | |
| | n | 391 | 392 | 392 | 393 | 393 | 393 | | | | | | | | |
| ΣOH-PAHs | Pearson's r | 0.29 | 0.99 | 0.32 | 0.26 | 0.25 | 0.24 | 1 | | | | | | | |
| | n | 391 | 391 | 391 | 391 | 391 | 391 | 391 | | | | | | | |
| HCC | Pearson's r | 0.14 | 0.02 | 0.09 | 0.06 | 0.06 | 0.05 | 0.02 | 1 | | | | | | |
| | n | 391 | 392 | 392 | 393 | 393 | 393 | 391 | 393 | | | | | | |
| Leukocytes | Pearson's r | 0.03 | 0.02 | 0.07 | 0.11 | 0.02 | -0.02 | 0.02 | 0.07 | 1 | | | | | |
| | n | 391 | 392 | 392 | 393 | 393 | 393 | 391 | 393 | 393 | | | | | |
| Neutrophils | Pearson's r | 0.08 | 0.07 | 0.11 | 0.12 | 0.04 | 0.02 | 0.07 | 0.12 | 0.90 | 1 | | | | |
| | n | 391 | 392 | 392 | 393 | 393 | 393 | 391 | 393 | 393 | 393 | | | | |
| Lymphocytes | Pearson's r | -0.06 | -0.04 | -0.06 | -0.02 | -0.06 | -0.08 | -0.05 | -0.08 | 0.45 | 0.09 | 1 | | | |
| | n | 391 | 392 | 392 | 393 | 393 | 393 | 391 | 393 | 393 | 393 | 393 | | | |
| Monocytes | Pearson's r | 0.01 | -0.08 | -0.01 | 0.06 | 0.01 | -0.05 | -0.07 | 0.06 | 0.57 | 0.41 | 0.30 | 1 | | |
| | n | 391 | 392 | 392 | 393 | 393 | 393 | 391 | 393 | 393 | 393 | 393 | 393 | | |
| NLR | Pearson's r | 0.10 | 0.09 | 0.13 | 0.12 | 0.07 | 0.06 | 0.09 | 0.15 | 0.53 | 0.82 | -0.49 | 0.19 | 1 | |
| | n | 391 | 392 | 392 | 393 | 393 | 393 | 391 | 393 | 393 | 393 | 393 | 393 | 393 | |
| 8-oxodG | Pearson's r | 0.10 | 0.02 | 0.03 | 0.17 | 0.09 | -0.09 | 0.02 | -0.05 | -0.02 | -0.01 | -0.04 | -0.03 | 0.02 | 1 |
| | n | 391 | 392 | 392 | 393 | 393 | 393 | 391 | 393 | 393 | 393 | 393 | 393 | 393 | 393 |

All biomarkers are ln-transformed. Significant correlations ($p \leq 0.05$) are marked in bold. Urinary biomarkers are normalized for urinary specific gravity. Abbreviations: PAH polycyclic aromatic hydrocarbon, 1-OHPy 1-hydroxypyrene, 2-OHNa 2-hydroxynaphthalene, 2,3-OHFl sum of 2-hydroxyfluorene and 3-hydroxyfluorene, 2-OHPH 2-hydroxyphenanthrene, 3-OHPH 3-hydroxyphenanthrene, 1,9-OHPH sum of 1-hydroxyphenanthrene and 9-hydroxyphenanthrene, Σ OH-PAHs sum of molar concentrations of all measured OH-PAHs, HCC hair cortisol concentration, NLR neutrophil-to-lymphocyte ratio, 8-oxodG 8-oxo-7,8-dihydro-2'-deoxyguanosine.

Table S2. Detection frequency and limit of quantification (LOQ, $\mu\text{g/L}$) for OH-PAHs in urine in the fourth Flemish Environment and Health Study (FLEHS-4).

| Biomarker | LOQ ($\mu\text{g/L}$) | % > LOQ |
|----------------|-------------------------|---------|
| OH-PAHs | | |
| 2-OHNa | 0.150 | 100 |
| 2,3-OHFl | 0.030 | 99.5 |
| 2-OHPH | 0.015 | 97.6 |
| 3-OHPH | 0.014 | 98.8 |
| 4-OHPH | 0.014 | 6.9 |
| 1,9-OHPH | 0.031 | 98.1 |
| 1-OHPy | 0.015 | 97.6 |

Abbreviations: PAH polycyclic aromatic hydrocarbon, 1-OHPy 1-hydroxypyrene, 2-OHN 2-hydroxynaphthalene, 2,3-OHF sum of 2-hydroxyfluorene and 3-hydroxyfluorene, 2-OHPH 2-hydroxyphenanthrene, 3-OHPH 3-hydroxyphenanthrene, 1,9-OHPH sum of 1-hydroxyphenanthrene and 9-hydroxyphenanthrene, LOQ limit of quantification.

Table S3. Significance of associations between study population characteristics and OH-PAHs in univariate analysis.

| | 2-OHNa | 2,3-OHFl | 2-OHPH | 3-OHPH | 1,9-OHPH | 1-OHPy | Σ OHPy |
|------------------------------------|--------------------------|--|--|--|--|--------------------------|---------------|
| Sex | | | | | | | |
| Male | reference | reference | reference | reference | reference | reference | reference |
| Female | 1.32 (1.11, 1.57) | 1.02 (0.91, 1.14) 0.90 (0.80, 1.00) | 0.90 (0.81, 1.00) | 1.08 (0.95, 1.22) | 1.06 (0.94, 1.19) | 1.27 (1.08, 1.49) | |
| Age | | | | | | | |
| < 14.5 | reference | reference | reference | reference | reference | reference | reference |
| 14.5–15.5 | 1.15 (0.94, 1.40) | 1.14 (1.00, 1.24) 1.13 (0.99, 1.28) | 1.17 (1.04, 1.32) 1.28 (1.11, 1.48) | 1.28 (1.11, 1.48) 1.22 (1.07, 1.40) | 1.22 (1.07, 1.40) 1.16 (1.11, 1.48) | | |
| > 15.5 | 1.19 (0.84, 1.69) | 1.35 (1.07, 1.69) 1.29 (1.03, 1.61) | 1.26 (1.02, 1.56) 1.24 (0.96, 1.59) | 1.22 (0.96, 1.53) | 1.21 (0.88, 1.68) | | |
| Body Mass Index | | | | | | | |
| Underweight | reference | reference | reference | reference | reference | reference | reference |
| Normal weight | 1.11 (0.81, 1.53) | 1.06 (0.86, 1.30) 1.19 (0.97, 1.47) | 1.07 (0.88, 1.30) | 1.13 (0.90, 1.43) | 1.05 (0.86, 1.39) | 1.10 (0.82, 1.47) | |
| Overweight, obese | 1.58 (1.10, 2.26) | 1.30 (1.03, 1.63) 1.46 (1.15, 1.84) | 1.06 (0.85, 1.32) | 1.13 (0.87, 1.48) | 1.09 (0.86, 1.39) | 1.49 (1.07, 2.08) | |
| Perceived income adequacy | | | | | | | |
| Difficult | reference | reference | reference | reference | reference | reference | reference |
| Rather easy | 0.79 (0.63, 0.98) | 0.85 (0.74, 0.99) 0.87 (0.76, 1.01) | 0.90 (0.78, 1.03) | 0.93 (0.79, 1.10) | 0.87 (0.75, 1.01) | 0.79 (0.65, 0.97) | |
| Easy to very easy | 0.73 (0.59, 0.90) | 0.79 (0.69, 0.90) 0.76 (0.66, 0.87) | 0.84 (0.74, 0.96) 0.91 (0.78, 1.06) | 0.83 (0.72, 0.96) 0.73 (0.60, 0.89) | | | |
| Area Deprivation Index | | | | | | | |
| 0–5.3% | reference | reference | reference | reference | reference | reference | reference |
| 5.4–9.3% | 0.98 (0.76, 1.26) | 1.18 (1.01, 1.38) 1.14 (0.97, 1.34) | 1.08 (0.93, 1.26) | 0.99 (0.83, 1.19) | 1.14 (0.97, 1.35) | 0.98 (0.78, 1.23) | |
| 9.4–15.5% | 1.21 (0.94, 1.54) | 1.23 (1.05, 1.44) 1.17 (1.05, 1.38) | 1.12 (0.96, 1.30) | 1.03 (0.86, 1.23) | 1.08 (0.92, 1.27) | 1.21 (0.96, 1.52) | |
| > 15.5% | 1.03 (0.80, 1.31) | 1.09 (0.93, 1.28) 1.22 (1.04, 1.43) | 1.11 (0.95, 1.29) | 0.95 (0.79, 1.14) | 1.04 (0.89, 1.23) | 1.03 (0.82, 1.29) | |
| Smoking | | | | | | | |
| No | reference | reference | reference | reference | reference | reference | reference |
| Yes | 1.88 (1.23, 2.88) | 2.49 (1.92, 3.23) 2.27 (0.97, 1.67) | 1.27 (0.98, 1.64) | 1.28 (0.94, 1.72) | 1.24 (0.93, 1.66) | 1.81 (1.21, 2.70) | |
| Residential exposure to ETS | | | | | | | |
| No | reference | reference | reference | reference | reference | reference | reference |
| Yes | 1.28 (0.96, 1.70) | 1.36 (1.14, 1.64) 1.34 (1.12, 1.62) | 1.22 (1.03, 1.45) 1.07 (0.87, 1.31) | 1.09 (1.06, 1.56) 1.25 (0.96, 1.63) | | | |
| Season | | | | | | | |
| Winter | reference | reference | reference | reference | reference | reference | reference |
| Spring | 0.84 (0.69, 1.03) | 1.14 (1.02, 1.29) 1.30 (1.14, 1.47) | 1.22 (1.08, 1.37) 1.16 (1.01, 1.34) | 1.14 (1.00, 1.30) 0.86 (0.72, 1.04) | | | |
| Summer | - | - | - | - | - | - | - |
| Fall | 0.96 (0.76, 1.22) | 1.08 (0.92, 1.26) 1.13 (0.97, 1.31) | 0.98 (0.85, 1.13) | 0.80 (0.67, 0.95) | 0.96 (0.82, 1.12) | 0.96 (0.77, 1.20) | |
| 2-day mean temperature (°C) | | | | | | | |
| < 6 | reference | reference | reference | reference | reference | reference | reference |
| 6–12 | 0.83 (1.68, 1.02) | 1.02 (0.90, 1.16) 1.10 (0.98, 1.26) | 1.03 (0.91, 1.17) | 0.98 (0.84, 1.14) | 0.95 (0.86, 1.09) | 0.85 (0.70, 1.03) | |
| > 12 | 0.85 (0.68, 1.05) | 1.22 (1.06, 1.40) 1.36 (1.19, 1.56) | 1.29 (1.14, 1.47) 1.15 (0.98, 1.35) | 1.14 (0.98, 1.32) | 0.86 (0.71, 1.06) | | |
| Recent health complaints | | | | | | | |
| No | reference | reference | reference | reference | reference | reference | reference |
| Yes | 1.09 (0.90, 1.32) | 0.97 (0.86, 1.10) 0.98 (0.87, 1.11) | 0.95 (0.85, 1.07) | 0.92 (0.80, 1.06) | 0.97 (0.86, 1.10) | 1.08 (0.90, 1.29) | |

All biomarkers are ln-transformed. Significant correlations ($p \leq 0.05$) are marked in bold. Abbreviations: OH-PAHs hydroxylated polycyclic aromatic hydrocarbon, 2-OHNa 2-hydroxy-naphthalene, 2,3-OHFl sum of 2-hydroxy-fluorene and 3-hydroxy-fluorene, 2-OHPH 2-hydroxy-phenanthrene, 3-OHPH 3-hydroxy-phenanthrene, 1,9-OHPH sum of 1-hydroxy-phenanthrene and 9-hydroxy-phenanthrene, 1-OHPy 1-hydroxy-pyrene, Σ OHPy sum of molar concentrations of all measured OH-PAHs, ETS environmental tobacco smoke.

Table S4. Significance of associations between study population characteristics and effect biomarkers in univariate analysis.

| | HCC | Leucocytes | Neutrophils | Lymphocytes | Monocytes | NLR | 8-oxodG |
|---------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|---------------------------|--------------------------|
| Sex | | | | | | | |
| Male | reference | reference | reference | reference | reference | reference | reference |
| Female | 1.14 (0.98, 1.33) | 1.08 (1.03, 1.13) | 1.21 (1.13, 1.31) | 0.96 (0.92, 1.01) | 0.97 (0.92, 1.03) | 1.26 (1.16, 1.387) | 1.01 (0.93, 1.10) |
| Age | | | | | | | |
| < 14.5 | reference | reference | reference | reference | reference | reference | reference |
| 14.5–15.5 | 1.13 (0.95, 1.35) | 1.04 (0.99, 1.10) | 1.09 (1.00, 1.09) | 1.00 (0.95, 1.06) | 1.03 (0.96, 1.10) | 1.09 (0.98, 1.20) | 1.02 (0.92, 1.13) |
| > 15.5 | 1.39 (1.03, 1.89) | 1.10 (1.00, 1.21) | 1.17 (1.01, 1.36) | 1.01 (0.92, 1.12) | 0.98 (0.87, 1.10) | 1.15 (0.97, 1.37) | 1.14 (0.96, 1.35) |
| Body Mass Index | | | | | | | |
| Underweight | reference | reference | reference | reference | reference | reference | reference |
| Normal weight | 1.08 (0.82, 1.43) | 1.00 (0.91, 1.09) | 0.97 (0.85, 1.12) | 1.05 (0.96, 1.15) | 0.98 (0.88, 1.09) | 0.92 (0.79, 1.08) | 1.00 (0.85, 1.17) |
| Overweight, obese | 1.21 (0.88, 1.66) | 1.06 (0.96, 1.18) | 1.10 (0.94, 1.29) | 1.06 (0.95, 1.17) | 1.00 (0.87, 1.11) | 1.05 (0.87, 1.25) | 0.98 (0.82, 1.17) |
| Perceived Income | | | | | | | |
| Adequacy | | | | | | | |
| Difficult | reference | reference | reference | reference | reference | reference | reference |
| Rather easy | 0.88 (0.72, 1.07) | 1.02 (0.96, 1.09) | 1.00 (0.90, 1.10) | 1.05 (0.98, 1.123) | 1.03 (0.96, 1.11) | 0.95 (0.85, 1.06) | 0.94 (0.84, 1.05) |
| Easy to very easy | 0.82 (0.68, 1.00) | 1.01 (0.95, 1.07) | 0.98 (0.90, 1.08) | 1.02 (0.96, 1.09) | 1.00 (0.93, 1.07) | 0.96 (0.86, 1.07) | 0.95 (0.85, 1.06) |
| Area Deprivation Index | | | | | | | |
| 0–5.3% | reference | reference | reference | reference | reference | reference | reference |
| 5.4–9.3% | 0.94 (0.76, 1.17) | 1.01 (0.94, 1.058) | 1.00 (0.90, 1.12) | 1.00 (0.93, 1.07) | 0.9 (0.91, 1.07) | 1.00 (0.89, 1.14) | 1.03 (0.91, 1.17) |
| 9.4–15.5% | 1.03 (0.83, 1.28) | 0.97 (0.91, 1.04) | 0.98 (0.88, 1.09) | 0.96 (0.90, 1.03) | 0.97 (0.89, 1.05) | 1.01 (0.90, 1.15) | 1.02 (0.90, 1.15) |
| > 15.5% | 1.02 (0.82, 1.27) | 1.04 (0.97, 1.11) | 1.05 (0.94, 1.17) | 1.00 (0.93, 1.07) | 1.03 (0.95, 1.12) | 1.06 (0.93, 1.20) | 1.01 (0.89, 1.14) |
| Smoking | | | | | | | |
| No | reference | reference | reference | reference | reference | reference | reference |
| Yes | 1.11 (0.77, 1.59) | 1.03 (0.92, 1.16) | 1.05 (0.87, 1.26) | 1.01 (0.90, 1.14) | 1.00 (0.87, 1.15) | 1.03 (0.84, 1.27) | 1.15 (0.93, 1.41) |
| Residential exposure to | | | | | | | |
| ETS | | | | | | | |
| No | reference | reference | reference | reference | reference | reference | reference |
| Yes | 0.83 (0.64, 1.07) | 1.09 (1.01, 1.19) | 1.10 (0.97, 1.25) | 1.10 (1.01, 1.19) | 1.03 (0.94, 1.14) | 1.00 (0.86, 1.15) | 1.21 (1.05, 1.39) |
| Season | | | | | | | |
| Winter | reference | reference | reference | reference | reference | reference | reference |
| Spring | 1.10 (0.92, 1.31) | 1.02 (0.96, 1.08) | 1.00 (0.92, 1.09) | 1.05 (0.99, 1.11) | 1.01 (0.94, 1.08) | 0.95 (0.86, 1.05) | 0.99 (0.90, 1.410) |
| Summer | - | - | - | - | - | - | - |
| Fall | 1.21 (0.99, 1.50) | 1.02 (0.96, 1.09) | 1.03 (0.93, 1.15) | 0.98 (0.91, 1.04) | 1.01 (0.93, 1.09) | 1.06 (0.94, 1.19) | 1.08 (0.96, 1.22) |
| 2-day mean temp | | | | | | | |
| < 6 | - | reference | reference | reference | reference | reference | reference |
| 6–12 | - | 1.02 (0.96, 1.08) | 1.03 (0.94, 1.12) | 0.99 (0.93, 1.05) | 1.00 (0.93, 1.07) | 1.04 (0.94, 1.15) | 1.00 (0.91, 1.11) |
| > 12 | - | 0.98 (0.92, 1.04) | 0.92 (0.81, 1.01) | 1.06 (0.99, 1.12) | 1.00 (0.93, 1.08) | 0.87 (0.78, 0.97) | 0.96 (0.86, 1.07) |
| Recent health complaints | | | | | | | |
| No | - | reference | reference | reference | reference | reference | reference |
| Yes | - | 1.09 (1.04, 1.15) | 1.14 (1.05, 1.23) | 1.01 (0.93, 1.07) | 1.09 (1.02, 1.16) | 1.12 (1.02, 1.24) | 1.02 (0.93, 1.13) |

All biomarkers are ln-transformed. Significant correlations ($p \leq 0.05$) are marked in bold. 8-OHdG is adjusted for urinary specific gravity. ETS environmental tobacco smoke, HCC hair cortisol concentration, NLR neutrophil to lymphocyte ratio, 8-oxodG 8-oxo-7,8-dihydro-2'-deoxyguanosine.

Table S5. Significance of differences in associations between OH-PAHs and outcomes by sex.

| OH-PAHs | p-value of interaction by sex | | | | | | |
|-----------------|-------------------------------|------------|-------------|--------------|-----------|--------------|---------|
| | HCC | Leucocytes | Neutrophils | Lymphocytes | Monocytes | NLR | 8-oxodG |
| 2-OHNa | 0.067 | 0.240 | 0.271 | 0.384 | 0.570 | 0.649 | 0.449 |
| 2,3-OHFl | 0.154 | 0.239 | 0.979 | 0.012 | 0.305 | 0.147 | 0.991 |
| 2-OHPH | 0.079 | 0.706 | 0.920 | 0.477 | 0.310 | 0.739 | 0.697 |
| 3-OHPH | 0.235 | 0.700 | 0.942 | 0.456 | 0.630 | 0.616 | 0.940 |
| 1,9-OHPH | 0.485 | 0.325 | 0.204 | 0.602 | 0.202 | 0.205 | 0.300 |
| 1-OHPy | 0.642 | 0.264 | 0.544 | 0.407 | 0.447 | 0.963 | 0.799 |
| Σ OH-PAH | 0.580 | 0.849 | 0.625 | 0.470 | 0.275 | 0.398 | 0.332 |

Significance of the interaction term of OH-PAH and sex in models, adjusted for sex, age, BMI, household socio-economic status, season of sampling, smoking and residential exposure to environmental tobacco smoke is presented. Significant interactions (p -interaction ≤ 0.20) are marked in bold. Abbreviations: OH-PAHs hydroxylated polycyclic aromatic hydrocarbon, 1-OHPy 1-hydroxypyrene, 2-OHNa 2-hydroxynaphthalene, 2,3-OHFl sum of 2-hydroxyfluorene and 3-hydroxyfluorene, 2-OHPH 2-hydroxyphenanthrene, 3-OHPH 3-hydroxyphenanthrene, 1,9-OHPH sum of 1-hydroxyphenanthrene and 9-hydroxyphenanthrene, Σ OH-PAHs sum of molar concentrations of all measured OH-PAHs, HCC hair cortisol concentration, NLR neutrophil-to-lymphocyte ratio, 8-oxodG 8-oxo-7,8-dihydro-2'-deoxyguanosine.

Table S6. Linear regression analyses of urinary OH-PAHs concentrations, estimated effect for boys in girls of associations that significantly differed by sex.

| OH-PAHs | Boys | Girls |
|--|-------------------|--------------------------|
| | β (95% CI) | β (95% CI) |
| HCC (pg/mg) | | |
| 2-OHNa | 1.05 (0.96, 1.15) | 0.93 (0.86, 1.02) |
| 2,3-OHFl | 1.13 (0.98, 1.30) | 0.99 (0.87, 1.14) |
| 2-OHPH | 1.11 (0.96, 1.28) | 0.95 (0.84, 1.08) |
| Lymphocytes (cells/μL) | | |
| 2,3-OHFl | 1.02 (0.97, 1.07) | 0.94 (0.90, 0.98) |
| neutrophil-to-lymphocyte ratio (NLR) | | |
| 2,3-OHFl | 1.02 (0.94, 1.10) | 1.10 (1.02, 1.18) |

Effect estimates β are presented with their 95% confidence interval (95% CI) as the factor change in hair cortisol concentration (HCC), lymphocyte count and neutrophil-to-lymphocyte ratio (NLR) for a doubling in OH-PAH concentration. Models adjusted for sex, age, BMI, household socio-economic status, season of sampling, smoking and residential exposure to environmental tobacco smoke and including the interaction term of each OH-PAH with sex. Significant associations are marked in bold. Abbreviations: OH-PAHs hydroxylated polycyclic aromatic hydrocarbon, 1-OHPy 1-hydroxypyrene, 2-OHNa 2-hydroxynaphthalene, 2,3-OHFl sum of 2-hydroxyfluorene and 3-hydroxyfluorene, 2-OHPH 2-hydroxyphenanthrene, 3-OHPH 3-hydroxyphenanthrene, 1,9-OHPH sum of 1-hydroxyphenanthrene and 9-hydroxyphenanthrene.

Table S7. Sensitivity analysis, main models of associations between urinary OH-PAHs concentrations and outcomes additionally adjusted for neighborhood socio-economic status.

| OH-PAHs | β (95% CI) | | | | | | |
|------------------|--------------------------|--------------------------|--------------------------|--------------------------|-------------------|--------------------------|--------------------------|
| | HCC | Leucocytes | Neutrophils | Lymphocytes | Monocytes | NLR | 8-oxodG |
| 2-OHNa | 0.98 (0.92, 1.05) | 1.00 (0.98, 1.02) | 1.00 (0.97, 1.04) | 0.99 (0.97, 1.01) | 0.98 (0.96, 1.00) | 1.01 (0.98, 1.05) | 1.01 (0.98, 1.05) |
| 2,3-OHFl | 1.06 (0.95, 1.18) | 1.01 (0.98, 1.05) | 1.04 (0.99, 1.09) | 0.97 (0.94, 1.01) | 1.00 (0.96, 1.04) | 1.07 (1.01, 1.13) | 1.04 (0.98, 1.10) |
| 2-OHPH | 1.03 (0.93, 1.14) | 1.03 (1.00, 1.06) | 1.06 (1.01, 1.11) | 0.98 (0.95, 1.01) | 1.02 (0.98, 1.06) | 1.08 (1.02, 1.14) | 1.08 (1.02, 1.14) |
| 3-OHPH | 1.06 (0.95, 1.17) | 1.01 (0.97, 1.04) | 1.02 (0.97, 1.08) | 0.97 (0.94, 1.00) | 1.00 (0.96, 1.05) | 1.06 (1.00, 1.12) | 1.06 (1.00, 1.12) |
| 1,9-OHPH | 1.02 (0.94, 1.12) | 0.99 (0.96, 1.02) | 1.00 (0.96, 1.04) | 0.97 (0.94, 1.00) | 0.99 (0.95, 1.02) | 1.03 (0.98, 1.03) | 1.01 (0.96, 1.06) |
| 1-OHPy | 1.13 (1.03, 1.25) | 1.00 (0.97, 1.03) | 1.02 (0.97, 1.07) | 0.98 (0.95, 1.01) | 1.00 (0.97, 1.04) | 1.05 (0.99, 1.10) | 1.07 (1.02, 1.13) |
| Σ OH-PAHs | 0.98 (0.91, 1.05) | 1.00 (0.98, 1.02) | 1.01 (0.98, 1.04) | 0.99 (0.97, 1.01) | 0.98 (0.96, 1.01) | 1.02 (0.98, 1.06) | 1.02 (0.98, 1.06) |

Effect estimates β are presented with their 95% confidence interval (95% CI) as the factor change in HCC, leucocyte count or NLR for a doubling in OH-PAH concentration. Models are adjusted for sex, age, BMI, household socio-economic status, neighborhood socio-economic status, season, smoking and residential exposure to environmental tobacco smoke. Significant associations (p -value ≤ 0.05) are marked in bold. Abbreviations: OH-PAHs hydroxylated polycyclic aromatic hydrocarbon, 1-OHPy 1-hydroxypyrene, 2-OHNa 2-hydroxynaphthalene, 2,3-OHFl sum of 2-hydroxyfluorene and 3-hydroxyfluorene, 2-OHPH 2-hydroxyphenanthrene, 3-OHPH 3-hydroxyphenanthrene, 1,9-OHPH sum of 1-hydroxyphenanthrene and 9-hydroxyphenanthrene, Σ OH-PAHs sum of molar concentrations of all measured OH-PAHs, HCC hair cortisol concentration, 8-oxodG 8-oxo-7,8-dihydro-2'-deoxyguanosine, NLR neutrophil-to-lymphocyte ratio.

Table S8. Sensitivity analysis, main models of associations between urinary OH-PAHs concentrations and 8-OHdG, leucocyte counts and NLR additionally adjusted for 2-day mean ambient temperature.

| OH-PAHs | β (95% CI) | | | | | | |
|------------------|--------------------------|--------------------------|--------------------------|-------------------|--------------------------|--------------------------|--|
| | Leucocytes | Neutrophils | Lymphocytes | Monocytes | NLR | 8-oxodG | |
| 2-OHNa | 1.00 (0.98, 1.02) | 1.01 (0.97, 1.04) | 0.99 (0.97, 1.01) | 0.98 (0.96, 1.00) | 1.01 (0.98, 1.05) | 1.01 (0.98, 1.05) | |
| 2,3-OHFl | 1.01 (0.98, 1.05) | 1.04 (0.99, 1.09) | 0.97 (0.94, 1.00) | 1.00 (0.96, 1.04) | 1.07 (1.01, 1.14) | 1.05 (0.99, 1.11) | |
| 2-OHPH | 1.03 (1.00, 1.07) | 1.07 (1.01, 1.12) | 0.98 (0.95, 1.01) | 1.02 (0.98, 1.06) | 1.09 (1.03, 1.15) | 1.08 (1.02, 1.14) | |
| 3-OHPH | 1.01 (0.97, 1.04) | 1.03 (0.98, 1.08) | 0.97 (0.93, 1.00) | 1.00 (0.96, 1.04) | 1.06 (1.00, 1.13) | 1.06 (1.00, 1.12) | |
| 1,9-OHPH | 0.99 (0.96, 1.01) | 0.99 (0.95, 1.04) | 0.97 (0.94, 1.00) | 0.98 (0.95, 1.02) | 1.02 (0.97, 1.07) | 1.01 (0.96, 1.06) | |
| 1-OHPy | 1.00 (0.97, 1.03) | 1.02 (0.97, 1.07) | 0.97 (0.94, 1.00) | 1.00 (0.97, 1.04) | 1.05 (0.99, 1.11) | 1.07 (1.02, 1.13) | |
| Σ OH-PAHs | 1.00 (0.98, 1.02) | 1.01 (0.98, 1.04) | 0.99 (0.97, 1.01) | 0.98 (0.96, 1.01) | 1.02 (0.98, 1.06) | 1.02 (0.98, 1.06) | |

Effect estimates β are presented with their 95% confidence interval (95% CI) as the factor change in leucocyte count or NLR for a doubling in OH-PAH concentration. Models are adjusted for sex, age, BMI, household socio-economic status, season of sampling, smoking and residential exposure to environmental tobacco smoke, 2-day mean ambient temperature. Models for 8-OHdG are additionally adjusted for urinary density. Significant associations (p -value ≤ 0.05) are marked in bold. Abbreviations: OH-PAHs hydroxylated polycyclic aromatic hydrocarbon, 1-OHPy 1-hydroxypyrene, 2-OHNa 2-hydroxynaphthalene, 2,3-OHFl sum of 2-hydroxyfluorene and 3-hydroxyfluorene, 2-OHPH 2-hydroxyphenanthrene, 3-OHPH 3-hydroxyphenanthrene, 1,9-OHPH sum of 1-hydroxyphenanthrene and 9-hydroxyphenanthrene, Σ OH-PAHs sum of molar concentrations of all measured OH-PAHs, 8-oxodG 8-oxo-7,8-dihydro-2'-deoxyguanosine, NLR neutrophil-to-lymphocyte ratio.

Table S9. Sensitivity analysis, main models of associations between urinary OH-PAHs and leucocyte counts and NLR additionally adjusted for recent health complaints.

| OH-PAHs | β (95% CI) | | | | |
|------------------|--------------------------|--------------------------|--------------------------|-------------------|--------------------------|
| | Leucocytes | Neutrophils | Lymphocytes | Monocytes | NLR |
| 2-OHNa | 1.00 (0.98, 1.02) | 1.00 (0.97, 1.04) | 0.99 (0.97, 1.01) | 0.98 (0.96, 1.00) | 1.01 (0.98, 1.05) |
| 2,3-OHFl | 1.01 (0.98, 1.04) | 1.03 (0.98, 1.09) | 0.97 (0.94, 1.00) | 1.00 (0.96, 1.04) | 1.07 (1.01, 1.13) |
| 2-OHPH | 1.03 (1.00, 1.06) | 1.06 (1.01, 1.11) | 0.98 (0.95, 1.01) | 1.02 (0.98, 1.06) | 1.08 (1.02, 1.14) |
| 3-OHPH | 1.00 (0.97, 1.04) | 1.02 (0.97, 1.07) | 0.97 (0.94, 1.00) | 1.00 (0.96, 1.04) | 1.06 (1.00, 1.12) |
| 1,9-OHPH | 0.99 (0.96, 1.02) | 1.00 (0.95, 1.04) | 0.97 (0.94, 1.00) | 0.99 (0.95, 1.02) | 1.03 (0.98, 1.08) |
| 1-OHPy | 1.00 (0.97, 1.03) | 1.02 (0.97, 1.07) | 0.97 (0.94, 1.01) | 1.00 (0.97, 1.04) | 1.04 (0.99, 1.10) |
| Σ OH-PAHs | 1.00 (0.98, 1.02) | 1.01 (0.97, 1.04) | 0.99 (0.97, 1.01) | 0.98 (0.96, 1.01) | 1.02 (0.98, 1.06) |

Effect estimates β are presented with their 95% confidence interval (95% CI) as the factor change in leucocyte count or NLR for a doubling in OH-PAH concentration. Models are adjusted for sex, age, BMI, household socio-economic status, season of sampling, smoking and residential exposure to environmental tobacco smoke, recent health complaints. Significant associations (p -value ≤ 0.05) are marked in bold. Abbreviations: OH-PAHs hydroxylated polycyclic aromatic hydrocarbon, 1-OHPy 1-hydroxypyrene, 2-OHNa 2-hydroxynaphthalene, 2,3-OHFl sum of 2-hydroxyfluorene and 3-hydroxyfluorene, 2-OHPH 2-hydroxyphenanthrene, 3-OHPH 3-hydroxyphenanthrene, 1,9-OHPH sum of 1-hydroxyphenanthrene and 9-hydroxyphenanthrene, Σ OH-PAHs sum of molar concentrations of all measured OH-PAHs, NLR neutrophil-to-lymphocyte ratio.

Table S10. Associations between HCC, 8-OHdG, leucocyte counts and NLR and between urinary OH-PAHs concentration and aforementioned outcomes in models adjusted for HCC.

| | Leucocytes | Neutrophils | Lymphocytes | Monocytes | NLR | 8-oxodG |
|------------------|--------------------------|--------------------------|--------------------------|-------------------|--------------------------|--------------------------|
| HCC | 1.01 (0.99, 1.03) | 1.03 (0.99, 1.07) | 0.98 (0.96, 1.01) | 1.02 (0.99, 1.05) | 1.05 (1.01, 1.09) | 0.98 (0.94, 1.02) |
| 2-OHNa | 1.00 (0.98, 1.02) | 1.01 (0.97, 1.04) | 0.99 (0.97, 1.01) | 0.98 (0.96, 1.01) | 1.01 (0.98, 1.05) | 1.01 (0.98, 1.05) |
| HCC | 1.01 (0.99, 1.03) | 1.03 (0.99, 1.07) | 0.98 (0.96, 1.01) | 1.02 (0.96, 1.04) | 1.05 (1.01, 1.09) | 0.98 (0.94, 1.02) |
| 2,3-OHF1 | 1.01 (0.98, 1.04) | 1.03 (0.98, 1.08) | 0.97 (0.94, 1.00) | 1.00 (0.96, 1.04) | 1.06 (1.00, 1.12) | 1.05 (0.99, 1.11) |
| HCC | 1.01 (0.99, 1.03) | 1.03 (0.99, 1.07) | 0.99 (0.96, 1.01) | 1.02 (0.96, 1.04) | 1.04 (1.00, 1.09) | 0.98 (0.94, 1.01) |
| 2-OHPH | 1.03 (1.00, 1.06) | 1.06 (1.01, 1.11) | 0.98 (0.95, 1.01) | 1.02 (0.98, 1.06) | 1.08 (1.02, 1.14) | 1.08 (1.02, 1.14) |
| HCC | 1.01 (0.99, 1.03) | 1.03 (0.99, 1.07) | 0.99 (0.96, 1.01) | 1.02 (0.96, 1.04) | 1.05 (1.01, 1.09) | 0.98 (0.94, 1.01) |
| 3-OHPH | 1.00 (0.97, 1.04) | 1.02 (0.97, 1.07) | 0.97 (0.94, 1.00) | 1.00 (0.96, 1.04) | 1.05 (0.99, 1.11) | 1.06 (1.00, 1.12) |
| HCC | 1.01 (0.99, 1.03) | 1.03 (0.99, 1.07) | 0.99 (0.96, 1.01) | 1.02 (0.96, 1.04) | 1.04 (1.00, 1.09) | 0.98 (0.94, 1.01) |
| 1,9-OHPH | 0.99 (0.96, 1.01) | 0.99 (0.95, 1.04) | 0.97 (0.94, 1.00) | 0.98 (0.95, 1.02) | 1.02 (0.97, 1.07) | 1.01 (0.96, 1.06) |
| HCC | 1.01 (0.99, 1.03) | 1.03 (0.99, 1.07) | 0.99 (0.96, 1.01) | 1.02 (0.96, 1.04) | 1.05 (1.01, 1.09) | 0.98 (0.94, 1.02) |
| 1-OHPy | 1.00 (0.97, 1.03) | 1.01 (0.96, 1.01) | 0.98 (0.95, 1.01) | 1.00 (0.96, 1.04) | 1.04 (0.98, 1.09) | 1.08 (1.02, 1.13) |
| HCC | 1.01 (0.99, 1.03) | 1.03 (0.99, 1.07) | 0.99 (0.96, 1.01) | 1.02 (0.96, 1.04) | 1.04 (1.00, 1.09) | 0.97 (0.93, 1.01) |
| Σ OH-PAHs | 1.00 (0.98, 1.02) | 1.01 (0.98, 1.05) | 0.99 (0.97, 1.01) | 0.98 (0.96, 1.01) | 1.02 (0.98, 1.06) | 1.02 (0.98, 1.06) |
| HCC | 1.01 (0.99, 1.03) | 1.03 (0.99, 1.07) | 0.98 (0.96, 1.01) | 1.02 (0.96, 1.04) | 1.05 (1.01, 1.09) | 0.98 (0.94, 1.02) |

Effect estimates β are presented with their 95% confidence interval (95% CI) as the factor change in leucocyte count or NLR for a doubling in OH-PAH concentration. Models are adjusted for sex, age, BMI, household socio-economic status, season of sampling, smoking and residential exposure to environmental tobacco smoke. Significant associations (p -value ≤ 0.05) are marked in bold. Abbreviations: PAH polycyclic aromatic hydrocarbon, 1-OHPy 1-hydroxypyrene, 2-OHNa 2-hydroxynaphthalene, 2,3-OHF1 sum of 2-hydroxyfluorene and 3-hydroxyfluorene, 2-OHPH 2-hydroxyphenanthrene, 3-OHPH 3-hydroxyphenanthrene, 1,9-OHPH sum of 1-hydroxyphenanthrene and 9-hydroxyphenanthrene, Σ OH-PAHs sum of molar concentrations of all measured OH-PAHs, 8-oxodG 8-oxo-7,8-dihydro-2'-deoxyguanosine, NLR neutrophil-to-lymphocyte ratio, HCC hair cortisol concentration.